Secondary and exploratory objectives include determination of PFS, OS in molecular subgroups (defined by EGFR and KRAS mutation status, amplification or overexpression of MET, and serum hepatocyte growth factor), and safety.
Given this genomic complexity and heterogeneity of IBCs, and the low degree of differences observed with nIBCs globally, future studies should ideally compare IBCs and nIBCs within molecular subgroups defined by expression (molecular subtypes) and/or by CNA (simplex, complex sawtooth, complex firestorm) profiles as recently suggested [60].
We have demonstrated the ability to identify the molecular subgroups previously defined within a cohort of sporadic, BRCA1 mutant and BRCA2 mutant FFPE breast tumours as well as defining two novel subgroups within this tumour set.
To assess the statistical relevance of the molecular subgroups as defined by the hierarchical clustering, we performed a Chi2 analysis of the data (see Methods).
The authors then investigated whether the TNP would accurately identify basal-like cancers, by assessing the correlation coefficient between the gene expression profiles of each TNP cancer and the centroids of the molecular subgroups as defined by Hu and colleagues [ 2].
From this combined analysis, we demonstrate that about 86% of all tumour biopsies classify strongly into one of the three molecular subgroups as defined by the available gene list from Freije et al., and for about 11%, there is strong evidence of a novel group of GBMs that share expression features of Pro and Mes subtypes from the bulk biopsy analysis.
However, since it is clear that BC is a molecular heterogeneous disease, with subgroups defined primarily by the estrogen (ER) and HER2 receptors, prognosis could be refined to these molecularly homogeneous subgroups of patients.
However, since it is clear that breast cancer is a molecular heterogeneous disease, with subgroups defined primarily by the estrogen (ER) and HER2 receptors (Perou et al., 2000; Sotiriou et al., 2003), prognosis could be refined to these molecularly homogeneous subgroups of patients.
These same models were applied to subgroups defined by molecular subtypes.
The same models were applied to subgroups defined by molecular subtypes.
Since previous studies have demonstrated a good resemblance of subgroups defined by common tumor markers to molecular subtypes defined by mRNA expression patterns [ 13, 14], we used cytosolic protein levels of ER and PgR and used TMA immunostaining of HER2, CK5/14 and EGFR to classify the material into five tumor subgroups.
